Valganciclovir 450 mg Tablets

Therapeutic Class: Antivirals​

Dosage Forms: Tablets

Brand Name: Valgan 450

Valganciclovir Tablets Tablets Manufacturers, Suppliers, and Exporters in India.

How it works?

Uses of Valganciclovir 450 mg Tablets

Vlganciclovir Tablets USP 450 mg – Vlganciclovir is indicated for the induction and maintenance treatment of cytomegalovirus (CMV) retinitis in adult patients with acquired immunodeficiency syndrome (AIDS).

Vlganciclovir is indicated for the prevention of CMV disease in CMV-negative adults and children (aged from birth to 18 years) who have received a solid organ transplant from a CMV-positive donor.

Dosages administration of Valganciclovir 450 mg Tablets

Vlganciclovir is administered orally, and whenever possible, should be taken with food.
For paediatric patients who are unable to swallow vlganciclovir film-coated tablets, vlganciclovir powder for oral solution can be administered.

Side effects of Valganciclovir 450 mg Tablets

Skin and subcutaneous tissues disorders:
Common: Night sweats, Pruritus, Rash, Alopecia

Renal and urinary disorders:
Common: Renal impairment, Creatinine clearance renal decreased, Blood creatinine increased

Respiratory, thoracic and mediastinal disorders:
Very common: Cough, Dyspnoea

Gastrointestinal disorders:
Very common: Diarrhoea, Nausea, Vomiting, Abdominal pain
Common: Dyspepsia, Flatulence, Abdominal pain upper, Constipation

Very common: Neutropenia, Anaemia
Common: Thrombocytopenia, Leukopenia, PancytopeniaRare: Aplastic anaemia, Agranulocytosis, Granulocytopenia

Immune system disorders:
Common: Hypersensitivity

Psychiatric disorders:
Common: Depression, Confusional state, Anxiety
Uncommon: Agitation, Psychotic disorder, Thinking abnormal, Hallucinations

Nervous system disorders:
Common: Insomnia, Neuropathy peripheral, Dizziness, Paraesthesia, Hypoaesthesia

Eye disorders:
Common: Visual impairment, Retinal detachment, Vitreous floaters, Eye pain, Conjunctivitis

Precautions of Valganciclovir 450 mg Tablets

Cross-hypersensitivity
Due to the similarity of the chemical structure of ganciclovir and that of aciclovir and penciclovir, a cross-hypersensitivity reaction between these drugs is possible.

Mutagenicity, teratogenicity, carcinogenicity, fertility, and contraception Prior to the initiation of vlganciclovir treatment, patients should be advised of the potential risks to the foetus.

Vlganciclovir should be considered a potential teratogen and carcinogen in humans with the potential to cause birth defects and cancers.

Vlganciclovir has the potential to cause carcinogenicity and reproductive toxicity in the long term.

Myelosuppression
Severe leukopenia, neutropenia, anaemia, thrombocytopenia, pancytopenia, bone marrow failure and aplastic anaemia have been7 observed in patients treated with vlganciclovir (and ganciclovir).

Vlganciclovir should be used with caution in patients with pre-existing haematological cytopenia or a history of drug-related haematological cytopenia and in patients receiving radiotherapy.

Difference in bioavailability with oral ganciclovir The bioavailability of ganciclovir after a single dose of 900 mg vlganciclovir is approximately 60 %, compared with approximately 6 % after administration of 1000 mg oral ganciclovir (as capsules). When switching from induction to maintenance therapy and in patients who may switch from oral ganciclovir to vlganciclovir as vlganciclovir cannot be substituted for ganciclovir capsules on a one-to-one basis.

Renal impairment
In patients with impaired renal function, dosage adjustments based on creatinine clearance are required. Vlganciclovir film-coated tablets should not be used in patients on haemodialysis.

Storage instruction of Valganciclovir 450 mg Tablets

Store below 30oC. Protect from light and moisture.
Keep the medicine out of reach of children.

Packing details of Valganciclovir 450 mg Tablets

10 × 1 × 10 Alu/Alu Blister.
Vlgan 450 tablets are available in an Alu/Alu blister of 10 tablets. Such 01 blister in a monocarton and Such 10 monocartons in a unit carton with pack insert.

interested? let’s talk.

Contact us directly to receive full information on the product, the formulation, the science behind it, stability data, and more. Our Business Development Manager is a click away.

Please enable JavaScript in your browser to complete this form.

Get Your Business Quote in 24 Hour

Fill out the form below, and we will be in touch shortly.
Please enable JavaScript in your browser to complete this form.